Nocira

Nocira operates at the intersection of medical devices, digital health and migraine therapeutics, with a differentiated approach based on non-invasive air-pressure stimulation rather than medication, injections, electrical stimulation or magnetic pulses. Its investigational system delivers modulated pressure changes through the ear to stimulate pressure-sensitive sensory nerves and influence pain-processing pathways. That mechanism places Nocira in the broader neuromodulation and acute-migraine-treatment landscape, alongside companies developing external nerve stimulation, wearable devices and prescription digital therapies. However, the available company record does not identify validated direct competitors, comparative clinical outcomes or a current regulatory status, so relative market share and differentiation cannot be quantified. Nocira’s potential distinction lies in combining an ear-based pressure device with smartphone control and planned smart-technology capabilities intended to learn from treatment use. Its intellectual-property activity is also specific: filings cover ear-canal pressure regulation, ear pumps and a magnetically driven pressure generator, while the company reports 20 granted patents and one registered trademark.

Nocira’s trajectory shows a transition from company formation and financing into technology refinement and clinical-development work. The company was founded in 2017 and announced a $9.5 million Series B on Jun 12, 2017, led by AZ Crown Investments. Its product architecture combines an investigational non-invasive migraine device, a smartphone-controlled mobile application and a clinical-trial program designed to evaluate safety and effectiveness in a double-blinded, randomized, placebo-controlled, multi-center setting. The technology development timeline is visible in a sequence of patent publications: an external ear canal pressure regulation device in 2021, ear pumps in 2022, additional pressure-regulation filings in 2022 and 2024, and a magnetically driven pressure generator in 2023. This progression suggests ongoing engineering and protection of the core delivery system rather than a rapid expansion into multiple product categories. Nocira reports 20 granted patents and one registered trademark, reinforcing the emphasis on intellectual property. The organization remains small, with an employee band of one to ten and five listed current positions. The clearest inflection points are the 2017 financing and the 2021-2024 patent activity.